免疫检查点抑制剂相关肺炎的临床诊治建议
Open Access
- 20 October 2019
- journal article
- review article
- Vol. 22 (10) , 621-626
Abstract
免疫检查点抑制剂在肿瘤中的使用给晚期肿瘤患者带来了新的希望。然而,由免疫检查点抑制剂激活的免疫系统,其中主要是T细胞免疫,可能攻击人体正常组织器官导致相应的免疫毒性反应产生,在肺部可引起免疫检查点抑制剂相关肺炎。这是一类不同于已知肺部间质性肺炎的疾病,如处理不当,有潜在的致命风险。我们将对免疫检查点抑制剂相关肺炎的诊断和治疗给予建议。Keywords
This publication has 20 references indexed in Scilit:
- Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With CancerJAMA Oncology, 2019
- The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-AnalysisFrontiers in Pharmacology, 2018
- Immune Checkpoint Immunotherapy for Non-Small Cell Lung CancerChest, 2018
- Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancerLung Cancer, 2018
- Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockadeJournal of Oncology Pharmacy Practice, 2017
- Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung CancerChest, 2017
- Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary TuberculosisJournal of Thoracic Oncology, 2016
- Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case seriesCancer Immunology, Immunotherapy, 2016
- Opportunistic infections in patients treated with immunotherapy for cancerJournal for ImmunoTherapy of Cancer, 2014
- Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old DrugsNew England Journal of Medicine, 2005